Navigation Links
Jazz Pharmaceuticals Announces Third Quarter 2013 Financial Results
Date:11/5/2013

owing updated 2013 guidance:Revenues

$867-$877 millionTotal Net Product Sales

$860-$870 million-Xyrem Net Sales

$565-$570 million-Erwinaze/Erwinase Net Sales

$173-$178 millionAdjusted Gross Margin %1,3

88-90%Adjusted Combined SG&A and R&D Expenses2,3

$275-$280 millionGAAP Net Income Per Diluted Share

$3.63-$3.79Adjusted Net Income Per Diluted Share3

$6.30-$6.401.

Excludes $4 million of acquisition accounting inventory fair value step-up adjustments and $3 million in share-based compensation expense from estimated GAAP gross margin of 87-89%.2.

Excludes $42 million of share-based compensation expense, $15 million related to a change in fair value of contingent consideration, $3 million of depreciation expense, $5 million of upfront license fees and $3 million of transaction, integration and restructuring costs from estimated GAAP combined SG&A and R&D expenses of $343-$348 million.3.

See "Non-GAAP Financial Measures" below. Reconciliations of non-GAAP adjusted guidance measures are included above and in the tables accompanying this press release.Conference Call DetailsJazz Pharmaceuticals will host an investor conference call and live audio webcast today at 4:30 p.m. EST (9:30 p.m. GMT) to provide a business update and discuss its third quarter 2013 results and updated 2013 financial guidance. The live webcast may be accessed from the Investors & Media section of the company's website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary. Investors may participate in the conference call by dialing +1 800 591 6942 in the U.S., or +1 617 614 4909 outside the U.S., and entering passcode 48257479.

A replay of the conference call will be availabl
'/>"/>

SOURCE Jazz Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig
2. Aquavit Pharmaceuticals Adds New Advanced Drug Delivery Technology to Product Portfolio
3. Jazz Pharmaceuticals to Present at the 2013 Credit Suisse Healthcare Conference on November 12
4. Immune Pharmaceuticals Appoints Liquidity Provider to Facilitate Trading on NASDAQ OMX Stockholm Exchange
5. Actinium Pharmaceuticals to Host Corporate Update and Virtual Roadshow Conference Call on November 11
6. Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
7. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, November 7
8. Merrimack Pharmaceuticals Announces Results From A Phase 2 Study Of MM-121 (SAR256212) In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers
9. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
10. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2013 Financial Results On November 5, 2013
11. Cumberland Pharmaceuticals To Announce Third Quarter 2013 Financial Results On November 5, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015  PinnacleHealth CardioVascular Institute enrolled the first patient ... the United States in a trial assessing ... for blockages in the main artery of the leg. The ... potentially less risk for stent fracture or re-narrowing after the ... multicenter clinical trial of the BioMimics 3D Stent System and ...
(Date:8/27/2015)... YORK , August 27, 2015 ... published by Persistence Market Research titled "Global Market ... Witness Highest Growth by 2021", the urinary catheters market is ... the end of 2015. It is anticipated to ... 2021, to reach US$1,755.0 Mn by 2021. ...
(Date:8/27/2015)... 2015  QB3@953—a San Francisco ... California (UC) research institute and biotech accelerator— today ... identify and facilitate collaborations to translate early drug ... The agreement formalizes a relationship between QB3@953 ... and creates a new channel for DPAc to ...
Breaking Medicine Technology:First Pennsylvania Patient Treated in Landmark Vascular Study 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 3Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 4QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2
... Berger Health System, recognized as one of the ... to AutoCarousel® HD by Talyst, a leader of pharmacy ... has a built-to-last 10 years guarantee. Berger ... is also implementing AutoPharm®, AutoPack™ and AutoLabel® to help ...
... Lineagen, Inc., an innovative molecular diagnostics company focused on ... nonprofit subsidiary of the National Multiple Sclerosis Society, today ... validation of a blood-based assay for multiple sclerosis (MS). ... test that can aid clinicians in diagnosing MS, distinguishing ...
Cached Medicine Technology:Berger Health System Partners With Pharmacy Automation Leader to Improve Patient Safety 2Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 2Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 3Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 4
(Date:8/27/2015)... ... August 27, 2015 , ... Cytovance® Biologics, ... biopharmaceutical contract development manufacturing company (CDMO), announced today that it has entered into ... in cash. , The addition of Cytovance Biologics to Hepalink USA ...
(Date:8/27/2015)... ... 27, 2015 , ... Susan Harris and the team at LifeStream ... to pre- and post-menopause, chemotherapy, and child birth. , The MonaLisa Touch ... to the vaginal tissue, revitalizing cells so they make more collagen, an essential component ...
(Date:8/27/2015)... Rocky Hill, CT (PRWEB) , ... August 27, 2015 , ... ... Portal Companies List. , “The companies selected have the platforms required not only to ... training,” said Ken Taylor, President of Training Industry, Inc. , For six consecutive ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... firm that helps libraries, publishers and companies leverage key operational, technical, business ... the VIVO Project. Gunter Media Group, Inc., will provide VIVO related services ...
(Date:8/27/2015)... Newport Beach, CA (PRWEB) , ... August 27, ... ... services and products, announced today that the new issue of Chairside® magazine, its ... the latest issue, Volume 10, Issue 3, as well as past issues of ...
Breaking Medicine News(10 mins):Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 2Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 3Health News:DuraSpace Selects Gunter Media Group, Inc. as a Registered Service Provider for VIVO 2Health News:DuraSpace Selects Gunter Media Group, Inc. as a Registered Service Provider for VIVO 3Health News:Glidewell Laboratories Releases Latest Issue of Restorative Dentistry Magazine Chairside in Print and Online 2Health News:Glidewell Laboratories Releases Latest Issue of Restorative Dentistry Magazine Chairside in Print and Online 3
... , , BATESVILLE, Ind., and ... today announced a strategic partnership agreement to integrate the Radianse ... system. With this move, Hill-Rom intends to extend its ... financial and technical obstacles for health care customers as they ...
... NOVATO, Calif., Sept. 2 BioMarin Pharmaceutical Inc. (Nasdaq: ... Chief Financial Officer of BioMarin, will present a company update at the ... at 4:25 p.m. ET. , , Interested ... the investor section of the BioMarin website, www.BMRN.com . ...
... SOMERSET, N.J., Sept. 2 Meda Pharmaceuticals ... (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for ... rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% ... for patients who suffer from seasonal allergies. ASTEPRO Nasal Spray ...
... /PRNewswire-Asia/ -- RainEarth Inc.,(OTC Bulletin Board: RNER; "the Company") announced ... publicized the creation of "Opinions of the,CPC Central Committee and ... Health Care System" ("Opinion"). , The ... a,doctor more easily. Reduced cost is the short-term goal and ...
... , , , , ... Mass., Sept. 2 /PRNewswire-FirstCall/ -- ... company that is developing and marketing Levulan(R) Photodynamic Therapy (PDT) and ... Bob Doman, President and Chief Executive Officer, will present a corporate ...
... , , , ... , a medical device company, today announced that its ... the U.S. Food and Drug Administration (FDA) for the direct delivery ... may be in the treatment of cancer. , , ...
Cached Medicine News:Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 2Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 3Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 4Health News:BioMarin to Present at the Thomas Weisel Partners Healthcare Conference 2Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 2Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 3Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 4Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 5Health News:RainEarth (RNER) Complies with Chinese Medical Service Reforms to Provide Better and Cheaper Blood Dialysis 2Health News:RainEarth (RNER) Complies with Chinese Medical Service Reforms to Provide Better and Cheaper Blood Dialysis 3Health News:DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 2Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 3Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 4
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Similar to Model 530, but just 37 inches long and with only one drape....
2-ply material consisting of polyethylene film inner layer and non-woven outer layers....
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Medicine Products: